NASDAQ · HURA
TuHURA Biosciences, Inc.
$1.90-$0.16 (-7.77%)
TuHURA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.61% below the high.
Loading market information…
OTC · KRBP · USD
Stock price, earnings
Quote as of Apr 11, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Kiromic BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kiromic BioPharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kiromic BioPharma, Inc. is a biotechnology enterprise that harnesses artificial intelligence to advance allogeneic cell therapies. The company's core mission involves crafting multi-indication T-cell treatments, specifically engineered to combat solid tumors by leveraging the innate capabilities of Gamma Delta T cells. Its developmental pipeline includes ALEXIS-ISO-1, an allogeneic gamma delta CAR-T cell therapy targeting Isomesothelin, and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy designed to address PD-L1. Supporting its research and development efforts, the company holds licensing agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, maintains a collaborative partnership for R&D with Molipharma, S.R.L., and has established a strategic alliance with Leon Office (H.K.) Ltd. Founded in 2006, the entity was initially known as Kiromic, Inc. before officially changing its name to Kiromic BioPharma, Inc. in December 2019. Its operations are headquartered in Houston, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
$1.90-$0.16 (-7.77%)
TuHURA Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.61% below the high.
£5.66-£1.14 (-16.76%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 53.61% below the high.
$0.47$0.00 (0.0%)
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
$0.00$0.00 (0.0%)
CuraScientific Corp: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00+$0.00 (+900.0%)
Vitalibis, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00+$0.00 (+179,899.98%)
Pivotal Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 14.29% below the high.
$0.00+$0.00 (0.0%)
Advanced Proteome Therapeutics Corporation: Healthcare · Biotechnology.
$0.03$0.00 (0.0%)
TRACON Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.7% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
